Baolingbao Biology Co.,Ltd. (SHE:002286)
8.85
+0.34 (4.00%)
Oct 14, 2026, 12:55 PM CST
Baolingbao Biology Revenue
Baolingbao Biology had revenue of 748.27M CNY in the quarter ending June 30, 2026, with 4.73% growth. This brings the company's revenue in the last twelve months to 2.85B, up 8.89% year-over-year. In the year 2025, Baolingbao Biology had annual revenue of 2.75B with 14.54% growth. That makes Baolingbao Biology the 12,162nd largest company in the world by revenue and 2,079th in China.
Revenue (ttm)
2.85B
Revenue Growth
+8.89%
P/S Ratio
1.14
Revenue / Employee
1.89M
Employees
1,505
Market Cap
3.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.75B | 349.27M | 14.54% |
| Dec 31, 2024 | 2.40B | -122.16M | -4.84% |
| Dec 31, 2023 | 2.52B | -188.83M | -6.96% |
| Jan 1, 2023 | 2.71B | -52.23M | -1.89% |
| Jan 1, 2022 | 2.76B | 710.40M | 34.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Qingdao Vland Biotech INC. | 1.42B |
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shanghai Universal Biotech | 1.15B |
| Pulike Biological Engineering | 1.02B |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |
| Lifecome Biochemistry | 470.43M |
| Guanhao Biotech | 361.40M |
| Jiangsu Bioperfectus Technologies | 310.89M |